Other Events. On August 26, 2026, LeonaBio, Inc. (the “Company”) announced that it had enrolled the 500th subject in its ongoing Phase 3 ELAINE-3 clinical trial (NCT05696626) for lasofoxifene in combination with abemaciclib, a CDK4/6 inhibitor, as a targeted therapy for estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated metastatic breast cancer, following progression on aromatase inhibitors and CDK4/6 inhibitors (the “ELAINE-3 Trial”). In connection with the private placement finan…

Results of Operations and Financial Condition. On August 14, 2026, LeonaBio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1. I tem 7.01 Regulation FD Disclosure. The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the Company’s…

Results of Operations and Financial Condition. On May 7, 2026, LeonaBio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1. I tem 7.01 Regulation FD Disclosure. The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the Company’s web…

contains certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements are identified by such words as “believe,” “expect,” “anticipate” and words of similar import and are based on current expectations that involve risks and uncertainties, such as the Company’s plans, projections, objectives, expectations and intentions. All statements other than historical or current facts are forward-looking statem…

of the Sermonix Transaction, including regarding the Sermonix License and the Sermonix Securities Issuance, are incorporated herein by reference. The incorporated description of the material terms of the Sermonix License does not purport to be complete and is qualified in its entirety by reference to the full text of the Sermonix License, a copy of which is attached hereto as Exhibit 2.1. The incorporated description of the material terms of the Sermonix Securities Issuance is qualified in it…

Results of Operations and Financial Condition. On March 26, 2025, LeonaBio, Inc. (the “Company”) issued a press release reporting its financial results for the year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. I tem 7.01 Regulation FD Disclosure. On March 26, 2026, LeonaBio, Inc. posted on the investor relations page of its website at investors.leonabio.com an investor presentation furnished as Exhibit 99.2 to this Current Report on Form 8-K (the…

The filing is about the approval of a new equity incentive plan and the termination of an old one, which does not involve any changes in management or executive departures.

Chief Financial Officer — Robert Renninger: The filing details an amended change in control and severance agreement for the CFO, outlining severance benefits.

Unregistered Sales of Equity Securities. The descriptions in

Entry into a Material Definitive Agreement. Private Placement Financing On December 18, 2025, Athira Pharma, Inc. (the “ Company ” or “ Athira ”) entered into a securities purchase agreement (the “ PIPE Securities Purchase Agreement ”) with a select group of investors, including Commodore Capital LP (“ Commodore ”), TCG Crossover Management LLC (“ TGCX ”), Perceptive Advisors (“ Perceptive ”) and other accredited investors, one of which is affiliated with a member of the board of directors (t…

Regulation FD Disclosure. As previously reported, as of September 30, 2025, the Company had cash, cash equivalents and investments of $25.2 million. The Company expects that its existing cash resources as of September 30, 2025, when combined with the anticipated net proceeds to be received at the closing of the Private Placement, will enable the Company to fund its planned operations, including the ongoing development of lasofoxifene and ATH-1105, into 2028 (excluding any cash received from t…

is focused on lasofoxifene and ATH-1105. For additional information regarding Athira’s other product candidates and early compounds, please refer to the Company’s Annual Report on Form 10-K filed with the SEC on February 27, 2025 and the Company’s Quarterly Reports on Form 10-Q filed with the SEC on May 9, 2025, August 7, 2025 and November 6, 2025. Athira’s Pipeline Figure 1 below illustrates the current development stage of Athira’s lead therapeutic drug programs, following this transaction.…

Regulation FD Disclosure. As previously reported, as of September 30, 2025, the Company had cash, cash equivalents and investments of $25.2 million. The Company expects that its existing cash resources as of September 30, 2025, when combined with the anticipated net proceeds to be received at the closing of the Private Placement, will enable the Company to fund its planned operations, including the ongoing development of lasofoxifene and ATH-1105, into 2028 (excluding any cash received from t…

Entry into a Material Definitive Agreement. Private Placement Financing On December 18, 2025, Athira Pharma, Inc. (the “ Company ” or “ Athira ”) entered into a securities purchase agreement (the “ PIPE Securities Purchase Agreement ”) with a select group of investors, including Commodore Capital LP (“ Commodore ”), TCG Crossover Management LLC (“ TGCX ”), Perceptive Advisors (“ Perceptive ”) and other accredited investors, one of which is affiliated with a member of the board of directors (t…

is focused on lasofoxifene and ATH-1105. For additional information regarding Athira’s other product candidates and early compounds, please refer to the Company’s Annual Report on Form 10-K filed with the SEC on February 27, 2025 and the Company’s Quarterly Reports on Form 10-Q filed with the SEC on May 9, 2025, August 7, 2025 and November 6, 2025. Athira’s Pipeline Figure 1 below illustrates the current development stage of Athira’s lead therapeutic drug programs, following this transaction.…

Unregistered Sales of Equity Securities. The descriptions in

Results of Operations and Financial Condition. On November 6, 2025, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. I tem 7.01 Regulation FD Disclosure. The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the…

Material Modification to Rights of Security Holders. To the extent required by

Results of Operations and Financial Condition. On August 7, 2025, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. I tem 7.01 Regulation FD Disclosure. The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the Compan…

Results of Operations and Financial Condition. On May 9, 2025, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. I tem 7.01 Regulation FD Disclosure. The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the Company’…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 15, 2025, Athira Pharma, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) approving the transfer of the listing of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) from the Nasdaq Global Select Market to the Nasdaq Capital Market (the “Approval”). As previously reported on a Current Repo…

Results of Operations and Financial Condition. On February 27, 2025, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the year ended December 31, 2024. A copy of the press release is furnished herewith as Exhibit 99.1. I tem 7.01 Regulation FD Disclosure. The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the Co…

Results of Operations and Financial Condition. On November 7, 2024, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended September 30, 2024. A copy of the press release is furnished herewith as Exhibit 99.1. I tem 7.01 Regulation FD Disclosure. The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 16, 2024, Athira Pharma, Inc. (the “Company”) received a notification letter (the “Bid Price Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, based on the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for the preceding 30 consecutive business days, the Compa…

Costs Associated with Exit or Disposal Activities. On September 15, 2024, Athira Pharma, Inc. (the “Company”) committed to a workforce reduction that is expected to result in the termination of approximately 49 positions, representing approximately 70% of the Company’s workforce (the “Restructuring”). The Company took this step to decrease its costs, extend its cash runway, and create a more streamlined organization to support its strategic priorities, including the continued development of A…